Richard Bruce Pearson

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/440048/publications.pdf

Version: 2024-02-01

134 papers	14,737 citations	15504 65 h-index	19190 118 g-index
140 all docs	140 docs citations	140 times ranked	17680 citing authors

#	Article	IF	Citations
1	Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma. Nature Communications, 2022, 13, 1100.	12.8	8
2	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. British Journal of Cancer, 2021, 124, 616-627.	6.4	26
3	Impaired ribosome biogenesis checkpoint activation induces p53-dependent MCL-1 degradation and MYC-driven lymphoma death. Blood, 2021, 137, 3351-3364.	1.4	13
4	Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. Signal Transduction and Targeted Therapy, 2021, 6, 323.	17.1	127
5	CX-5461 Sensitizes DNA Damage Repairâ€“proficient Castrate-resistant Prostate Cancer to PARP Inhibition. Molecular Cancer Therapeutics, 2021, 20, 2140-2150.	4.1	9
6	The RNA helicase Ddx21 controls Vegfc-driven developmental lymphangiogenesis by balancing endothelial cell ribosome biogenesis and p53 function. Nature Cell Biology, 2021, 23, 1136-1147.	10.3	17
7	A functional genetic screen defines the AKT-induced senescence signaling network. Cell Death and Differentiation, 2020, 27, 725-741.	11.2	40
8	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461. Frontiers in Cell and Developmental Biology, 2020, 8, 568.	3.7	15
9	CX-5461 can destabilize replication forks in PARP inhibitor-resistant models of ovarian cancer. Molecular and Cellular Oncology, 2020, 7, 1805256.	0.7	1
10	Reprogrammed <scp>mRNA</scp> translation drives resistance to therapeutic targeting of ribosome biogenesis. EMBO Journal, 2020, 39, e105111.	7.8	17
11	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. Nature Communications, 2020, 11, 2641.	12.8	90
12	Oncogene-induced senescence: From biology to therapy. Mechanisms of Ageing and Development, 2020, 187, 111229.	4.6	48
13	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYCâ€“Driven Cancer Progression. Cancer Research, 2020, 80, 3706-3718.	0.9	15
14	Regulation of PRMT5â€“MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17990-18000.	7.1	81
15	Neurokinin-1 receptor is an effective target for treating leukemia by inducing oxidative stress through mitochondrial calcium overload. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 19635-19645.	7.1	58
16	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. Oncogene, 2019, 38, 3824-3842.	5.9	17
17	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. Cancer Discovery, 2019, 9, 1036-1049.	9.4	129
18	Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation. Communications Biology, 2019, 2, 39.	4.4	33

#	Article	IF	Citations
19	Somatic mutations in early metazoan genes disrupt regulatory links between unicellular and multicellular genes in cancer. ELife, 2019, 8, .	6.0	50
20	Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4737-4742.	7.1	72
21	How the evolution of multicellularity set the stage for cancer. British Journal of Cancer, 2018, 118, 145-152.	6.4	89
22	Palbociclib synergizes with BRAF and MEK inhibitors in treatment naÃ¯ve melanoma but not after the development of BRAF inhibitor resistance. International Journal of Cancer, 2018, 142, 2139-2152.	5.1	56
23	Stage-dependent therapeutic efficacy in PI3K/mTOR-driven squamous cell carcinoma of the skin. Cell Death and Differentiation, 2018, 25, 1146-1159.	11.2	31
24	Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nature Communications, 2018, 9, 3970.	12.8	192
25	CystathionineÎ²-Synthase in Physiology and Cancer. BioMed Research International, 2018, 2018, 1-11.	1.9	74
26	Patient-derived Models of Abiraterone- and Enzalutamide-resistant Prostate Cancer Reveal Sensitivity to Ribosome-directed Therapy. European Urology, 2018, 74, 562-572.	1.9	80
27	A High-Throughput Screening Approach to Identify Therapeutics for the Treatment of Diamond-Blackfan Anaemia. Blood, 2018, 132, 3859-3859.	1.4	0
28	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription. Gene, 2017, 612, 36-48.	2.2	14
29	Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 6406-6411.	7.1	159
30	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	1.4	74
31	Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clinical Cancer Research, 2017, 23, 1862-1874.	7.0	107
32	The Potential of Targeting Ribosome Biogenesis in High-Grade Serous Ovarian Cancer. International Journal of Molecular Sciences, 2017, 18, 210.	4.1	20
33	Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. Genes, 2017, 8, 71.	2.4	78
34	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. Oncotarget, 2016, 7, 48887-48904.	1.8	8
35	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. Assay and Drug Development Technologies, 2016, 14, 416-428.	1.2	8
36	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. Clinical Cancer Research, 2016, 22, 5539-5552.	7.0	59

#	Article	IF	Citations
37	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. Cancer Discovery, 2016, 6, 59-70.	9.4	105
38	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. Oncotarget, 2016, 7, 49800-49818.	1.8	93
39	PR55Î±-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. Oncogene, 2015, 34, 1333-1339.	5.9	21
40	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	4.1	26
41	Unexpected role of CDK4 in a G2/M checkpoint. Cell Cycle, 2015, 14, 1351-1352.	2.6	5
42	S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila. Cellular Signalling, 2015, 27, 2045-2053.	3.6	15
43	The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma. Science Signaling, 2015, 8, ra82.	3.6	114
44	Regulation of rDNA transcription in response to growth factors, nutrients and energy. Gene, 2015, 556, 27-34.	2.2	79
45	A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes. Genome Research, 2015, 25, 201-212.	5.5	52
46	The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2015, 1849, 821-829.	1.9	105
47	Loss of <scp>CDKN</scp>2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the <scp>CDK</scp>4/6 inhibitor <scp>PD</scp>0332991 in melanoma cell lines. Pigment Cell and Melanoma Research, 2014, 27, 590-600.	3.3	165
48	Targeting the nucleolus for cancer intervention. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 802-816.	3.8	198
49	Response of BRAF-Mutant Melanoma to BRAF Inhibition Is Mediated by a Network of Transcriptional Regulators of Glycolysis. Cancer Discovery, 2014, 4, 423-433.	9.4	242
50	Widespread FRA1-Dependent Control of Mesenchymal Transdifferentiation Programs in Colorectal Cancer Cells. PLoS ONE, 2014, 9, e88950.	2.5	69
51	Targeting RNA polymerase I transcription and the nucleolus for cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 873-878.	3.4	55
52	Akt1 is the principal Akt isoform regulating apoptosis in limiting cytokine concentrations. Cell Death and Differentiation, 2013, 20, 1341-1349.	11.2	37
53	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. European Journal of Cancer, 2013, 49, 3936-3944.	2.8	72
54	<scp>AKT</scp> signalling is required for ribosomal <scp>RNA</scp> synthesis and progression of <scp>E</scp>Î¼â€Myc <scp>B</scp>â€cell lymphoma inÂvivo. FEBS Journal, 2013, 280, 5307-5316.	4.7	19

#	Article	IF	Citations
55	The mTORC1 Inhibitor Everolimus Prevents and Treats EÎ¼-Myc Lymphoma by Restoring Oncogene-Induced Senescence. Cancer Discovery, 2013, 3, 82-95.	9.4	58
56	Dysregulation of the basal RNA polymerase transcription apparatus in cancer. Nature Reviews Cancer, 2013, 13, 299-314.	28.4	187
57	Autophagy Induction Is a Tor- and Tp53-Independent Cell Survival Response in a Zebrafish Model of Disrupted Ribosome Biogenesis. PLoS Genetics, 2013, 9, e1003279.	3.5	73
58	Functional Analysis of Genes in Regions Commonly Amplified in High-Grade Serous and Endometrioid Ovarian Cancer. Clinical Cancer Research, 2013, 19, 1411-1421.	7.0	52
59	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood, 2013, 121, 2964-2974.	1.4	59
60	AKT-independent PI3-K signaling in cancer – emerging role for SGK3. Cancer Management and Research, 2013, 5, 281.	1.9	73
61	Too much or too little. Cell Cycle, 2012, 11, 3147-3148.	2.6	4
62	LRP1B Deletion in High-Grade Serous Ovarian Cancers Is Associated with Acquired Chemotherapy Resistance to Liposomal Doxorubicin. Cancer Research, 2012, 72, 4060-4073.	0.9	100
63	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. Oncogene, 2012, 31, 1949-1962.	5.9	221
64	Targeting PI3 Kinase/AKT/mTOR Signaling in Cancer. Critical Reviews in Oncogenesis, 2012, 17, 69-95.	0.4	204
65	Autophosphorylation of serine 608 in the p85 regulatory subunit of wild type or cancer-associated mutants of phosphoinositide 3-kinase does not affect its lipid kinase activity. BMC Biochemistry, 2012, 13, 30.	4.4	9
66	Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53. Cancer Cell, 2012, 22, 51-65.	16.8	468
67	An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. Journal of Clinical Investigation, 2012, 122, 553-557.	8.2	174
68	Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers. PLoS ONE, 2011, 6, e18064.	2.5	172
69	Targeting of the Tumor Suppressor GRHL3 by a miR-21-Dependent Proto-Oncogenic Network Results in PTEN Loss and Tumorigenesis. Cancer Cell, 2011, 20, 635-648.	16.8	203
70	A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. Cellular Signalling, 2011, 23, 1338-1347.	3.6	16
71	In silico modeling of the Menkes copper-translocating P-type ATPase 3rd metal binding domain predicts that phosphorylation regulates copper-binding. BioMetals, 2011, 24, 477-487.	4.1	6
72	Signaling to the ribosome in cancerâ€"It is more than just mTORC1. IUBMB Life, 2011, 63, 79-85.	3.4	35

#	Article	IF	Citations
73	Signaling to the ribosome in cancer-It is more than just mTORC1. IUBMB Life, 2011, 63, spcone-spcone.	3.4	0
74	Relative Expression Levels Rather Than Specific Activity Plays the Major Role in DeterminingIn VivoAKT Isoform Substrate Specificity. Enzyme Research, 2011, 2011, 1-18.	1.8	16
75	AKT Promotes rRNA Synthesis and Cooperates with c-MYC to Stimulate Ribosome Biogenesis in Cancer. Science Signaling, 2011, 4, ra56.	3.6	126
76	Drosophila Ribosomal Protein Mutants Control Tissue Growth Non-Autonomously via Effects on the Prothoracic Gland and Ecdysone. PLoS Genetics, 2011, 7, e1002408.	3.5	31
77	Determination of the Exact Molecular Requirements for Type 1 Angiotensin Receptor Epidermal Growth Factor Receptor Transactivation and Cardiomyocyte Hypertrophy. Hypertension, 2011, 57, 973-980.	2.7	27
78	Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias. Blood, 2011, 118, 1548-1548.	1.4	2
79	Myeloid progenitor cells lacking p53 exhibit delayed up-regulation of Puma and prolonged survival after cytokine deprivation. Blood, 2010, 115, 344-352.	1.4	29
80	Second AKT: The rise of SGK in cancer signalling. Growth Factors, 2010, 28, 394-408.	1.7	127
81	The multi-layered regulation of copper translocating P-type ATPases. BioMetals, 2009, 22, 177-190.	4.1	64
82	Phosphorylation regulates copper-responsive trafficking of the Menkes copper transporting P-type ATPase. International Journal of Biochemistry and Cell Biology, 2009, 41, 2403-2412.	2.8	52
83	Class IA Phosphatidylinositol 3-Kinase Signaling in Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2009, 4, 787-791.	1.1	30
84	UBF levels determine the number of active ribosomal RNA genes in mammals. Journal of Cell Biology, 2008, 183, 1259-1274.	5.2	171
85	Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. Blood, 2008, 112, 2305-2317.	1.4	92
86	Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors, 2007, 25, 209-226.	1.7	204
87	Mutation analysis ofPIK3CA andPIK3CB in esophageal cancer and Barrett's esophagus. International Journal of Cancer, 2006, 118, 2644-2646.	5.1	83
88	The Inositol Polyphosphate 5-Phosphatase, PIPP, Is a Novel Regulator of Phosphoinositide 3-Kinase-dependent Neurite Elongation. Molecular Biology of the Cell, 2006, 17, 607-622.	2.1	77
89	A Specific Role for AKT3 in the Genesis of Ovarian Cancer through Modulation of G2-M Phase Transition. Cancer Research, 2006, 66, 11718-11725.	0.9	85
90	Expression of stress response protein glucose regulated protein-78 mediated by c-Myb. International Journal of Biochemistry and Cell Biology, 2005, 37, 1254-1268.	2.8	36

#	Article	IF	Citations
91	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. EMBO Journal, 2004, 23, 3325-3335.	7.8	166
92	Mutation of the PIK3CA Gene in Ovarian and Breast Cancer. Cancer Research, 2004, 64, 7678-7681.	0.9	864
93	mTOR-Dependent Regulation of Ribosomal Gene Transcription Requires S6K1 and Is Mediated by Phosphorylation of the Carboxy-Terminal Activation Domain of the Nucleolar Transcription Factor UBFâ€. Molecular and Cellular Biology, 2003, 23, 8862-8877.	2.3	390
94	Protein kinase-dependent phosphorylation of the Menkes copper P-type ATPase. Biochemical and Biophysical Research Communications, 2003, 303, 337-342.	2.1	29
95	Activation of S6K1 (p70 ribosomal protein S6 kinase 1) requires an initial calcium-dependent priming event involving formation of a high-molecular-mass signalling complex. Biochemical Journal, 2003, 370, 469-477.	3.7	52
96	Direct Identification of Tyrosine 474 as a Regulatory Phosphorylation Site for the Akt Protein Kinase. Journal of Biological Chemistry, 2002, 277, 38021-38028.	3.4	88
97	Ro 31-6045, the inactive analogue of the protein kinase C inhibitor Ro 31-8220, blocks in vivo activation of p70s6k/p85s6k: implications for the analysis of S6K signalling. FEBS Letters, 2002, 519, 135-140.	2.8	15
98	The Synthetic Peptide RPRAATF Allows Specific Assay of Akt Activity in Cell Lysates. Analytical Biochemistry, 2002, 305, 32-39.	2.4	16
99	Phosphorylation of Nuclear Phospholipase C Î²1 by Extracellular Signal-Regulated Kinase Mediates the Mitogenic Action of Insulin-Like Growth Factor I. Molecular and Cellular Biology, 2001, 21, 2981-2990.	2.3	107
100	STIM1: a novel phosphoprotein located at the cell surface. BBA - Proteins and Proteomics, 2000, 1481, 147-155.	2.1	209
101	The Akt kinase signals directly to endothelial nitric oxide synthase. Current Biology, 1999, 9, 845-S1.	3.9	445
102	Dual posttranscriptional targets of retinoic acid-induced gene expression. Journal of Cellular Biochemistry, 1999, 72, 411-422.	2.6	0
103	Insulin and insulin antagonists evoke phosphorylation of P20 at serine 157 and serine 16 respectively in rat skeletal muscle. FEBS Letters, 1999, 462, 25-30.	2.8	25
104	Effects of wortmannin and rapamycin on CSF-1-mediated responses in macrophages. International Journal of Biochemistry and Cell Biology, 1998, 30, 271-283.	2.8	14
105	Phosphorylation Sites in the Autoinhibitory Domain Participate in p70s6k Activation Loop Phosphorylation. Journal of Biological Chemistry, 1998, 273, 14845-14852.	3.4	122
106	Differential Regulation by Calcium Reveals Distinct Signaling Requirements for the Activation of Akt and p70S6k. Journal of Biological Chemistry, 1998, 273, 4776-4782.	3.4	110
107	Dual Requirement for a Newly Identified Phosphorylation Site in p70^{s6k}. Molecular and Cellular Biology, 1997, 17, 5648-5655.	2.3	99
108	Rapamycin suppresses 5'TOP mRNA translation through inhibition of p70s6k. EMBO Journal, 1997, 16, 3693-3704.	7.8	833

#	Article	IF	Citations
109	Rapamycin, Wortmannin, and the Methylxanthine SQ20006 Inactivate p70s6k by Inducing Dephosphorylation of the Same Subset of Sites. Journal of Biological Chemistry, 1995, 270, 21396-21403.	3.4	161
110	Regulation of p70s6k/p85s6k and its role in the cell cycle. , 1995, 1, 21-32.		41
111	The immunosuppressant rapamycin induces inactivation of p70s6k through dephosphorylation of a novel set of sites. Journal of Biological Chemistry, 1993, 268, 16091-4.	3.4	100
112	Role of the pseudosubstrate sequence in smooth muscle myosin light chain kinase thermal stability. Journal of Biological Chemistry, 1993, 268, 12484-91.	3.4	5
113	Structural basis of the intrasteric regulation of myosin light chain kinases. Science, 1992, 258, 130-135.	12.6	126
114	Intrasteric regulation of protein kinases and phosphatases. Biochimica Et Biophysica Acta - Molecular Cell Research, 1991, 1094, 67-76.	4.1	146
115	[3] Protein kinase phosphorylation site sequences and consensus specificity motifs: Tabulations. Methods in Enzymology, 1991, 200, 62-81.	1.0	983
116	[10] Design and use of peptide substrates for protein kinases. Methods in Enzymology, 1991, 200, 121-134.	1.0	116
117	[24] Pseudosubstrate-based peptide inhibitors. Methods in Enzymology, 1991, 201, 287-304.	1.0	94
118	Proteolytic cleavage sites in smooth muscle myosin-light-chain kinase and their relation to structural and regulatory domains. FEBS Journal, 1991, 200, 723-730.	0.2	26
119	Regulatory and structural motifs of chicken gizzard myosin light chain kinase.. Proceedings of the National Academy of Sciences of the United States of America, 1990, 87, 2284-2288.	7.1	223
120	Protein kinase recognition sequence motifs. Trends in Biochemical Sciences, 1990, 15, 342-346.	7.5	1,036
121	Regulation of protein kinases by pseudosubstrate prototopes. Cellular Signalling, 1989, 1, 303-311.	3.6	29
122	Hydroxyamino acid specificity of smooth muscle myosin light chain kinase. Archives of Biochemistry and Biophysics, 1988, 260, 37-44.	3.0	5
123	Autoregulation of enzymes by pseudosubstrate prototopes: myosin light chain kinase. Science, 1988, 241, 970-973.	12.6	162
124	The calmodulin binding domain of chicken smooth muscle myosin light chain kinase contains a pseudosubstrate sequence. Journal of Biological Chemistry, 1987, 262, 2542-8.	3.4	164
125	Chemical modification of lysine and arginine residues in the myosin regulatory light chain inhibits phosphorylation. BBA - Proteins and Proteomics, 1986, 870, 312-319.	2.1	3
126	A potent synthetic peptide inhibitor of the cAMP-dependent protein kinase. Journal of Biological Chemistry, 1986, 261, 989-92.	3.4	444

#	Article	IF	Citations
127	Smooth muscle myosin kinase requires residues on the COOH-terminal side of the phosphorylation site. Peptide inhibitors. Journal of Biological Chemistry, 1986, 261, 25-7.	3.4	62
128	Spatial requirements for location of basic residues in peptide substrates for smooth muscle myosin light chain kinase. Journal of Biological Chemistry, 1985, 260, 3355-9.	3.4	79
129	Substrate specificity of a multifunctional calmodulin-dependent protein kinase. Journal of Biological Chemistry, 1985, 260, 14471-6.	3.4	151
130	Phosphorylation site sequence of smooth muscle myosin light chain (M r = 20 000). FEBS Letters, 1984, 168, 108-112.	2.8	99
131	Role of basic residues in the phosphorylation of synthetic peptides by myosin light chain kinase.. Proceedings of the National Academy of Sciences of the United States of America, 1983, 80, 7471-7475.	7.1	90
132	Myosin light chain kinase binding to plastic. FEBS Letters, 1982, 145, 327-331.	2.8	17
133	Phosphorylation of a synthetic heptadecapeptide by smooth muscle myosin light chain kinase. Journal of Biological Chemistry, 1982, 257, 13349-53.	3.4	21
134	Cystathionine-Î²-synthase is essential for AKT-induced senescence and suppresses the development of gastric cancers with PI3K/AKT activation. ELife, 0, 11, .	6.0	9